Thermo Fisher Scientific Inc.(TMO)Earnings, Financials & Key RatiosThermo Fisher Scientific Inc. (TMO) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
while the company maintains a forward P/E of 20.64, the extreme volatility in FCF margins—ranging from 3.5% to 30.5%—warrants caution regarding the sustainability of cash-funded growth.
Thermo Fisher Scientific Inc. (TMO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Thermo Fisher Scientific Inc. (TMO) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 23, 2026 | $5.44vs $5.25+3.6% | $11.0Bvs $10.9B+1.3% |
| Q1 2026 | Jan 29, 2026 | $6.57vs $6.45+1.9% | $12.2Bvs $11.9B+2.2% |
| Q4 2025 | Oct 22, 2025 | $5.79vs $5.50+5.3% | $11.1Bvs $10.9B+1.9% |
| Q3 2025 | Jul 23, 2025 | $5.36vs $5.23+2.5% | $10.9Bvs $10.7B+1.6% |
Recent stock market news and headlines for Thermo Fisher Scientific Inc. (TMO)
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is collaborating with Thermo Fisher Scientific Inc. (NYSE:TMO) to support the Phase 3 development and potential commercialization of ARCT-032, the company's investigational messenger RNA therapy for cystic fibrosis.
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the second quarter 2026 before the market opens on Thursday, July 23, 2026, and will hold a conference call on the same day at 8:30 a.m. ET. During the call, the company will discuss its financial performance, as well as future expectations. The call will be webcast live on the “Investors” section of our website, www.thermofish.
genedrive PLC (AIM:GDR, FRA:D6M) has signed a collaboration agreement with Thermo Fisher Scientific, sending its shares up 8% to 1.4p. The point-of-care pharmacogenetic testing company will develop a high-throughput laboratory test under the deal.
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, will showcase new capabilities, strategic investments and initiatives at BIO International 2026 that are helping pharma and biotech customers advance innovation, simplify complex workflows and bring therapies to patients faster. Spanning AI-enabled research, clinical development and advanced manufacturing, these investments reinforce Thermo Fisher's role as a trusted strategic provider of integrated.
Key metrics vs top competitors for Thermo Fisher Scientific Inc. (TMO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $516.62 | $191.99B | 29.12 | 3.91% | 15.12% | 13.06% | 0.33% | |
| $194.19 | $137.44B | 38.53 | 2.9% | 14.89% | 7.06% | — | |
| $131.14 | $37.04B | 28.70 | 6.73% | 19.55% | 20.84% | — | |
| $374.93 | $24.44B | 34.84 | 6.99% | 11.91% | 8.04% | — | |
| $292.50 | $7.9B | 10.50 | 0.65% | 6.52% | 2.4% | — | |
| $58.25 | $8.87B | -388.33 | 2.08% | -0.34% | -0.5% | — |
Thermo Fisher Scientific Inc. (TMO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Thermo Fisher Scientific Inc. (TMO) SEC filings — annual & quarterly reports (10-K, 10-Q)
Apr 23, 2026·SEC
Mar 24, 2026·SEC
Feb 12, 2026·SEC
Get notified when TMO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Thermo Fisher Scientific Inc. (TMO) stock FAQ — growth, dividends, profitability & financials explained
Thermo Fisher Scientific Inc. (TMO) reported $45.20B in revenue for fiscal year 2025. This represents a 1441% increase from $2.93B in 1996.
Thermo Fisher Scientific Inc. (TMO) grew revenue by 3.9% over the past year. Growth has been modest.
Yes, Thermo Fisher Scientific Inc. (TMO) is profitable, generating $6.86B in net income for fiscal year 2025 (15.1% net margin).
Yes, Thermo Fisher Scientific Inc. (TMO) pays a dividend with a yield of 0.33%. This makes it attractive for income-focused investors.
Thermo Fisher Scientific Inc. (TMO) has a return on equity (ROE) of 13.1%. This is reasonable for most industries.
Thermo Fisher Scientific Inc. (TMO) generated $6.75B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
